Journal Hepatology International

CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.

SS Zheng , JF Wu , WX Wu , ... , BH Zhang

10.1007/s12072-024-10696-0

Clinical evaluation of droplet digital pcr for suspected ascites infection in patients with liver cirrhosis.

J Han , FL Wei , HX Wu , ... , ZJ Hu

10.1007/s12072-024-10669-3

Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective

SE Keating , Y Chawla , A De , ES George

10.1007/s12072-024-10663-9

Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues.

S Yang , H Liang , X Li , ... , Z Ming

10.1007/s12072-024-10651-z

MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD.

WK Chan , VW Wong , LA Adams , MH Nguyen

10.1007/s12072-024-10661-x

Incidence, risk factors, and outcomes of acute liver injury in hospitalized adults with acute kidney injury: a large multicenter study

Y Lin , P Li , Y Zhang , ... , CRDS Study Investigators

10.1007/s12072-023-10627-5

MAFLD as part of systemic metabolic dysregulation

J Zhao , L Liu , YY Cao , ... , MH Zheng

10.1007/s12072-024-10660-y

Higher inflammatory response in hepatocellular carcinoma is associated with immune cell infiltration and a better outcome

M Oshi , K Chida , AM Roy , ... , K Takabe

10.1007/s12072-024-10678-2

Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002–2022

S Yu , J Li , T He , ... , R Wang

10.1007/s12072-024-10679-1

Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease

S Qin , X Cheng , S Zhang , ... , Z Yi

10.1007/s12072-024-10665-7